Top 5 Protein Expression Companies
.png)
Published: November 2024
These protein expression companies have the capability to offer higher yields, shorter development times and lower costs for the production of a broad range of target proteins.We analyzed the key companies that are engaged in providing protein expression solutions within the protein expression market. In this article, discover the 5 leading protein expression companies and their solutions related to protein expression market.
Proteins are biopolymeric molecules, comprising of long chains of amino acids folded into unique three dimensional shapes. These complex structures have diverse functions in the human body, including growth and repair of tissues, transporting molecules and regulating chemical reactions within the body. In the last two decades, owing to their metabolic stability, target specificity and versatility, proteins have extensively been researched for their applications as therapeutic agents. In this context, it is worth noting that since 1982, nearly 350 protein-based therapeutic drug products have been approved for the treatment of a myriad of disease indications. Considering the increasing demand for therapeutic proteins, industry stakeholders are actively utilizing novel technologies for the large scale production of proteins, such as protein expression.
Protein expression is a biotechnological process for synthesizing specific proteins using a cell’s machinery. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into polypeptide chains, which eventually gets folded to form functional proteins. The main components of protein expression include a vector (plasmid) containing the gene of interest, and a host cell (for instance, mammalian cell or E.coli). Using these components, protein expression in biotechnology is primarily being utilized for the manufacturing of various therapeutic modalities such as enzymes, antibodies and vaccines.
Other industry verticals benefiting from the protein expression process include agriculture, cosmetics, food, environmental sciences, biomedical research and enzyme synthesis industry. The potential of protein-based therapeutics is revolutionizing the healthcare landscape. Coupled with the ongoing research and development efforts, the industry stakeholders have been prompted to adopt novel protein expression systems for the development of recombinant proteins.
Roots Analysis has conducted an exhaustive study on Protein Expression Market featuring the current market landscape and future opportunity for the protein expression solution providers over a span of 10 years.
Table of Contents
The top 5 protein expression companies are listed below (in alphabetical order):
Table 1: List of Top 5 Protein Expression Companies
| S. No. | Protein Expression Companies | Year of Establishment | Location of Headquarters (Country) | Location of Headquarters |
| 1 | Agilent | 1999 | California, US | North America |
| 2 | Ajinomoto Bio-Pharma Services | 1909 | California, US | North America |
| 3 | Lonza | 1897 | Basel, Switzerland | Europe |
| 4 | Merck | 1668 | Hessen, Germany | Europe |
| 5 | WuXi Biologics | 2010 | Jiangsu, China | Asia-Pacific |
Interested in exploring players providing protein expression solutions?
Discover the Details on 5 Protein Expression Companies
This article highlights the top 5 players to watch out for in this industry. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Agilent, Having Significant Experience in the Field of Protein Expression, Offers a Number of Expression Systems and Products for Various Research Applications
 |
Agilent specializes in offering application focused solutions, including instruments, software, services and consumables for various laboratory purposes, and manufacturing of several advanced analytical, research, and diagnostic solutions and tools. The firm caters to the needs of six vital industries, including pharma and biotech, clinical and diagnostics, academia and government, environmental analysis and forensics, food safety and authentication and chemicals and energy. Further, leveraging its technical knowledge and operational expertise, the company provides contract development and manufacturing services for protein expression.
Agilent offers following Protein Expression Related Offerings:
- Protein Expression Systems
- Kits and Reagents
- Competent Cells
- Expression Vectors
Type of Protein Expression Systems Involved:
- Mammalian
- Prokaryotic
Application Area:
- Research
Recent Developments:
In April 2024, the company announced the appointment of Simon May as the President of the company’s Diagnostics and Genomics Group (DGG).
In February 2024, the company announced the appointment of Padraig McDonnell as the Chief Executive Officer.
In January 2024, the company participated in the Cambridge Healthtech Institute’s 26th Annual Recombinant Protein Expression & Production Conference to showcase its ProteoAnalyzer System, held in California, US.
To know more about Agilent and other protein expression companies providing solutions, access our full report.
Ajinomoto Bio-Pharma Services, Offers Tailored Solutions for Recombinant Proteins and Plasmid DNA
 |
Ajinomoto Bio-Pharma Services is a contract development and manufacturing organization with over 100 manufacturing facilities and offices across 35 different nations, worldwide. The company provides a wide portfolio of innovative platforms for recombinant protein expression. Further, the company is also engaged in offering high quality custom oligonucleotides, with its innovative AJIPHASE synthesis technology. In addition, the company claims to provide services related to antibody drug conjugate (ADCs), HPAPIs, oligonucleotides, and continuous manufacturing, at preclinical, clinical and commercial scales.
Ajinomoto Bio-Pharma Services offers following Protein-Expression Related Offerings:
- Protein Expression Systems
- Protein Expression Services
Type of Protein Expression System Involved:
- Prokaryotic
Application Area:
- Therapeutic
- Research
- Industrial
Recent Developments:
In January 2024, the company participated in the PEPTALK 2024 exhibition held in California, US, to discuss a wide range of topics, including protein expression platforms, antibody engineering, bispecific antibody development, characterization of biologics and viral vector engineering.
Further, in January 2024, the company participated in the Cambridge Healthtech Institute's 26th Annual Recombinant Protein Expression & Production conference, held in Massachusetts, US, to highlight its CDMO capabilities and showcase the Corynex protein and peptide expression platform technology and its applications.
To know more about Ajinomoto Bio-Pharma Services and other protein expression companies providing solutions, access our full report.
Lonza, Launching Novel and Improved Cell Lines, Expression Systems and Media to Meet the Evolving Needs of the Drug Developers
 |
Lonza, a Swiss drug manufacturing company is engaged in offering integrated solutions for research and development, and manufacturing of biologics to various industry, as well as non-industry stakeholders in the pharmaceutical, biotech and nutraceutical domain. Additionally, the company follows a B2B business model by extending its services to manufacturers of consumer health products, distributors, formulators and other service-based companies.
Lonza offers following Protein-Expression Related Offerings:
- Protein Expression Systems
- Reagents / Media
- Competent Cells
- Expression Vectors
- Protein Expression Services
Type of Protein Expression Systems Involved:
- Mammalian
- Prokaryotic
- Yeast
Application Area:
- Therapeutic
Recent Developments:
In July 2024, the company announced the commencement of Wolfgang Wienand role as New Chief Executive Officer.
In November 2023, Lonza launched a new cell line GS Effex® that produces Fc domains free of fucose. It leads to an increase of the antibody-dependent cellular cytotoxicity (ADCC) function and therapeutic potency of the final antibody.
In July 2023, the company launched a new TheraPRO CHO Media System in order to optimize the production of therapeutic proteins from GS-CHO cell lines.
Further, in July 2023, the company expanded its protein expression capabilities through the opening of a new facility in Slough, UK. The new facility will increase the capacity for early preclinical expression and in vitro immunogenicity services, thereby, optimizing drug candidates at initial stage.
To know more about Lonza and other protein expression companies providing solutions, access our full report.
Merck, Providing a Breadth of Transfection Reagents and Protein Expression
 |
Merck is a pharmaceutical manufacturing firm that is engaged in the development and commercialization of solutions for research and production of biopharmaceutical and pharmaceutical therapies. The company claims to offer one of the broadest portfolios in the industry and prominent products for pharmaceutical manufacturing and development. Within its life sciences division, Merck offers a wide range of products and services related to protein expression, from gene cloning to protein expression and purification, catering to the needs of various pharma / biopharma, and academic and industrial researchers. The firm strives to develop products that enhance the ecological footprint, as well as help its clients to meet sustainability goals.
Merck offers following Protein-Expression Related Offerings:
- Protein Expression Systems
- Kits and Reagents
- Competent Cells
- Expression Vectors
- Protein Expression Services
Type of Protein Expression System Involved:
- Mammalian
- Prokaryotic
- Insect
- Cell-free
Application Area:
- Therapeutic
- Research
- Industrial
Recent Developments:
In May 2024, the company participated in the Cambridge Healthtech Institute’s 3rd Annual Maximizing Protein Production Workflows Conference to discuss key factors (including expression system utilized, ability to improve the properties of the subject protein and purification process utilized) to consider to increase both the quantity and quality of the recombinant protein, held in California, US.
In March 2024, the company expanded its protein expression capabilities through the opening of a new bioprocessing production center for the development and production of biologics, in South Korea, China.
To know more about Merck and other protein expression companies providing solutions, access our full report.
WuXi Biologics, Excels in Ensuring Quality and Scalability of its Protein Expression and Protein Purification Processes, Catering to the Diverse Needs of their Clients
 |
WuXi Biologics is engaged in offering production and purification services for recombinant proteins, fc-fusion proteins, monoclonal, bispecific and multispecific antibodies. Through its Protein Sciences Department, the company specializes in providing high quality and scalable protein production for research purposes. This is achieved through their expertise in biologics development and the use of advanced expression systems. Further, the company has established quality control system to meet or exceed the regulatory standards of different agencies across the world, including Brazilian Health Regulatory Agency (ANVISA), European Medicines Agency (EMA), Food and Drug Administration (FDA), Health Canada, Health Sciences Authority (HSA), Ministry of Food and Drug Safety of the Republic of Korea (MFDS), National Medical Products Administration (NMPA) and Pharmaceuticals and Medical Devices Agency (PMDA). It is worth noting that, in April 2024, WuXi Biologics won 2024 CDMO Leadership Awards for the seventh consecutive year.
WuXi Biologics offers following Protein-Expression Related Offerings:
- Protein Expression Systems
- Competent Cells
- Protein Expression Services
Type of Protein Expression System Involved:
- Mammalian
- Prokaryotic
- Insect
- Yeast
- Cell-free
Application Area:
- Therapeutic
- Research
- Industrial
Recent Developments:
In March 2023, the company expanded its protein expression capabilities by offering development and cGMP manufacturing of microbial-derived products using its E.coli and yeast expression platforms.
To know more about WuXi Biologics and other protein expression companies providing solutions, access our full report.
What About the Other Players Providing Protein Expression Solutions?
The above presentation features 5 protein expression companies selected from a pool of more than 180 protein expression solution providers. If you are interested, you can download the Sample Report on “Protein Expression Market, till 2035” by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
1. “Simon May”
https://www.agilent.com/about/newsroom/presrel/2024/29apr-gp24008.html
2. “Padraig McDonnell”
https://www.agilent.com/about/newsroom/presrel/2024/21feb-gp24006.html
3. “26th Annual Recombinant Protein Expression & Production Conference”
https://www.chi-peptalk.com/protein-expression-production/
4. “PEPTALK 2024”
https://ajibio-pharma.ajinomoto.com/news/2312261/
5. “Wolfgang Wienand”
https://www.lonza.com/news/2024-07-01-07-00
6. “TheraPRO CHO Media System”
https://bioscience.lonza.com/lonza-launches-therapro-cho-media-system
7. “vitro immunogenicity services”
https://www.lonza.com/media-advisories/2023-02-13-14-00
8. “3rd Annual Maximizing Protein Production Workflows Conference”
https://www.pegsummit.com/protein-production
9. “Microbial-derived products”